| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 272 | 323 | 853 | 564 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 154 | 189 | 627 | 445 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 118 | 133 | 226 | 118 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 40 % | 38 % | 25 % | 19 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 17 | 20 | 54 | 45 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 2 | 3 | 10 | 10 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 100 | 110 | 161 | 63 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 18 | 26 | 44 | 16 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 82 | 83 | 117 | 46 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.23 | 3.26 | 3.16 | 1.28 |
Cohance Lifesciences
Cohance Lifesciences
864.45
-9.60
(-1.10%)
Key Fundamentals
Market Cap
33,071.02 Cr
EPS
10.52
PE Ratio
94.53
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
1,360.00
52 Week Low
856.30
PB Ratio
19.44
Debt to Equity
0.09
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from7 analysts
Actual
Company News
View All News
Jusmiral Holdings Limited, a promoter of Cohance Lifesciences Limited, sold 3,41,48,000 shares on September 18, 2025, through an on-market transaction. The sale reduced Jusmiral Holdings' stake in Cohance Lifesciences from 33.08% to 24.15%. The proceeds from the share sale will be used primarily for partial repayment of borrowings under a Notes Purchase Agreement dated May 29, 2024. The transaction was disclosed under SEBI Takeover Regulations and involved the release of certain encumbrances related to disposal restrictions on the shares. Cohance Lifesciences Limited was formerly known as Suven Pharmaceuticals Limited and is listed on BSE and NSE.
Jusmiral Holdings Limited, a promoter of Cohance Lifesciences Limited, sold 3,41,48,000 shares on September 18, 2025, through the National Stock Exchange. The transaction reduced Jusmiral Holdings' stake from 33.08% to 24.15%. The sale proceeds will be used primarily for part payment of borrowings under a Notes Purchase Agreement that was disclosed on May 9, 2025. The shares were sold through on-market transactions, and the disclosure was made in compliance with SEBI's Prohibition of Insider Trading Regulations.
Cohance Lifesciences saw 3.39 crore shares (8.9% equity) worth ₹3,073 crore change hands through block deals, with the stock declining over 6% in opening trading. Jusmiral Holdings sold the 8.9% stake for $350 million. The offer had a floor price of ₹900 per share, representing a 6.9% discount to the previous close. A 210-day lock-up period has been set for further share sales. IIFL Capital served as the book-running lead manager. Jusmiral Holdings held 33.34% stake in the company at the end of June quarter. Cohance Lifesciences is a Hyderabad-based contract development and manufacturing organisation serving international pharma, biotech and fine chemicals companies. The company changed its name from Suven Pharmaceuticals in May 2025. Shares closed the previous session 2.5% lower at ₹965.5, with the stock gaining 7.6% in the past month but declining 9.7% over six months.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,641.10 | #1 3,93,754.86 | 34.59 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 58.61 | |
6,248.50 | 1,65,878.04 | 67.06 | 9,712.00 | 18.67 | 2,191 | 26.74 | 55.71 | |
1,499.80 | 1,21,146.96 | 22.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 43.23 | |
3,538.00 | 1,19,742.00 | 59.08 | 11,539.40 | 6.99 | 1,911 | 19.91 | 44.81 | |
1,236.90 | 1,03,233.38 | #1 18.34 | 33,741.20 | 16.73 | 5,725 | 1.26 | 43.06 | |
2,453.90 | 1,01,286.81 | 53.53 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 43.39 | |
988.80 | 99,496.42 | 21.46 | 23,511.00 | 18.55 | 4,615 | 2.60 | 43.26 | |
1,914.50 | 87,445.65 | 23.93 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 43.17 | |
5,476.00 | 65,473.79 | 28.86 | 13,458.30 | 3.70 | 2,216 | 21.39 | 58.14 | |
30,140.00 | 64,045.40 | 43.95 | 6,684.70 | 9.64 | 1,414 | 11.55 | 36.86 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
12.83 %
Net Income Growth
-11.82 %
Cash Flow Change
-25.11 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-17.81 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 |
| Total Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 385 | 288 |
| Financing Activities | 26 | 7 | -76 | -157 | -242 | -40 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Nov 2025 |  Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 874.05 |
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 |  Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 | Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
5 minutes ago
5 minutes agoClosure of Trading Window10 days ago
10 days agoBoard Meeting Intimation for Considering And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ending September 30 2025.10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025
Sep 24, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 22, 2025
Sep 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Sep 22, 2025
Sep 22, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 19, 2025
Sep 19, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 19, 2025
Sep 19, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 19, 2025
Sep 19, 2025Clarification On Reported News In Electronic MediaSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Sep 18, 2025Disclosure Under SEBI PIT RegulationsSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Sep 15, 2025Completion Of USFDA InspectionSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 07, 2025
Sep 07, 2025Letter To Shareholders Regarding Annual ReportAug 28, 2025
Aug 28, 2025General AnnouncementAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 27, 2025
Aug 27, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Notice Of AGMAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Completion Of USFDA InspectionAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Giving Of Corporate GuaranteeJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 22, 2025
Jul 22, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsJul 19, 2025
Jul 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 02, 2025
Jul 02, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ending June 30 2025Jun 27, 2025
Jun 27, 2025Disclosure Under Regulation 30 Of The SEBI Listing RegulationsJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Jun 20, 2025Disclosure Regarding Sale Of Assets Of Clinical Research And Bio-Analytical Studies Site (CR Bio) Of The Company.Jun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Mutual Fund Holdings
HDFC Flexi Cap Direct Plan-Growth 
DSP Healthcare Fund Direct - Growth 
Invesco India Contra Fund Direct-Growth 
Axis Small Cap Fund Direct-Growth 
Canara Robeco Small Cap Fund Direct - Growth 
360 ONE Focused Fund Direct-Growth 
Tata Small Cap Fund Direct - Growth 
Mirae Asset Healthcare Fund Direct - Growth 
HSBC Small Cap Fund Direct-Growth 
SBI Healthcare Opportunities Fund Direct Plan-Growth 
Aditya Birla Sun Life Mid Cap Direct Fund-Growth 
JM Flexicap Fund Direct Plan-Growth 
Edelweiss Multi Cap Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 38.39
ATR(14)
Less Volatile 28.02
STOCH(9,6)
Neutral 24.35
STOCH RSI(14)
Oversold 13.69
MACD(12,26)
Bearish -4.49
ADX(14)
Weak Trend 18.92
UO(9)
Bearish 49.46
ROC(12)
Downtrend But Slowing Down -4.23
WillR(14)
Oversold -87.77
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
